Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Tribute to Prof. Jules Angst highlighting his Contributions to Clozapine.

Pharmacopsychiatry·2026
Same author

Beliefs about relationships between symptoms and experiences in daily life: Evidence from experience sampling and self-report in individuals with or without major depression or social phobia.

Behaviour research and therapy·2026
Same author

[Treatment recommendations for chronic insomnia - cognitive behavioural therapy as first-line treatment].

Praxis·2025
Same author

Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders: a systematic review and network meta-analysis.

European archives of psychiatry and clinical neuroscience·2025
Same author

Report from the WPA Section on Psychiatry and Sleep-Wakefulness Disorders.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2025
Same author

Correspondence between the Simple Physical Activity Questionnaire (SIMPAQ) and accelerometer-based physical activity in inpatients treated for major depressive disorders in comparison to non-depressed controls.

Frontiers in sports and active living·2024
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Related Experiment Videos

[Mood stabilizers].

Martin Hatzinger1

  • 1Psychiatrische Poliklinik, Universitätsspital Basel. mhatzinger@uhbs.ch

Therapeutische Umschau. Revue Therapeutique
|June 5, 2009
PubMed
Summary
This summary is machine-generated.

The diagnosis of bipolar disorders has evolved into a spectrum, increasing prevalence. Differentiating bipolar I and II, and considering rapid cycling, is crucial for effective mood stabilizer treatment selection.

Related Experiment Videos

Area of Science:

  • Psychiatry and Neurobiology
  • Pharmacology

Context:

  • Bipolar disorder diagnostic criteria have broadened, shifting from a singular manic-depressive illness to a spectrum disorder.
  • This evolution has led to increased prevalence estimates in the general population.
  • Clinical distinctions, such as between bipolar I and bipolar II disorders, are increasingly vital for tailored treatment strategies.

Purpose:

  • To review the evolving diagnostic landscape of bipolar disorders.
  • To examine the implications of these changes for psychopharmacological treatment selection.
  • To highlight the importance of specific clinical features in guiding mood stabilizer choice.

Summary:

  • Mood stabilizer selection for bipolar disorder is complex, influenced by episode type (euphoric vs. dysphoric mania), severity, and frequency.
  • Lithium and Valproate remain first-line options, with Lamotrigine indicated for bipolar depression.
  • Carbamazepine's first-line status has diminished, while atypical antipsychotics show efficacy in acute mania, depression, and prophylaxis.

Impact:

  • The complexity of psychopharmacological indications necessitates clear, evidence-based treatment guidelines.
  • Understanding the spectrum of bipolar disorder aids in more precise differential diagnosis.
  • Refined treatment algorithms can improve patient outcomes by optimizing mood stabilizer selection.